Modeling stroke management: A qualitative review of cost-effectiveness analyses

European Journal of Health Economics

Volumn 11, Issue 4, 2010, Pages 419-426

  Guilhaume, Chantal ^a   Saragoussi, Delphine ^a   Cochran, John ^a   François, Clément ^a   Toumi, Mondher ^b  

^a Lundbeck   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Cost effectiveness analysis; Decision analytic model; Disease management; Markov model; Pharmacoeconomic model; Stroke

Indexed keywords

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONSENSUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; ECONOMICS; EPIDEMIOLOGICAL DATA; LIFESPAN; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE;

COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FRANCE; HUMANS; MARKOV CHAINS; MEDLINE; MODELS, ECONOMIC; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; STROKE;

EID: 77954905741     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-010-0228-4     Document Type: Review

References (46)

1. Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S.M., Ho, M., Howard, V., Kissela, B., Kittner, S., Lloyd-Jones, D., McDermott, M., Meigs, J., Moy, C., Nichol, G., O'Donnell, C., Roger, V., Sorlie, P., Steinberger, J., Thom, T., Wilson, M., Hong, Y.: Heart disease and stroke statistics- 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), 25-146 (2008)
2. Wolfe, C.D., Giroud, M., Kolominsky-Rabas, P., Dundas, R., Lemesle, M., Heuschmann, P., Rudd, A.: Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke 31(9), 2074-2079 (2000)
3. Mayo, N.E., Wood-Dauphinee, S., Ahmed, S., Gordon, C., Higgins, J., McEwen, S., Salbach, N.: Disablement following stroke. Disabil. Rehabil. 21(5-6), 258-268 (1999)
4. Van Den Bos, G.A.M.: The burden of chronic diseases in terms of disability, use of health care and healthy life expectancies. Eur. J. Public Health 5(1), 29-34 (1995)
5. Patel, M.D., Tilling, K., Lawrence, E., Rudd, A.G., Wolfe, C.D., McKevitt, C.: Relationships between long-term stroke disability, handicap and health-related quality of life. Age Ageing 35(3), 273-279 (2006)
6. Haacke, C., Althaus, A., Spottke, A., Siebert, U., Back, T., Dodel, R.: Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 37(1), 193-198 (2006)
7. Pohjasvaara, T., Vataja, R., Leppavuori, A., Kaste, M., Erkinjuntti, T.: Cognitive functions and depression as predictors of poor outcome 15 months after stroke. Cerebrovasc. Dis. 14(3-4), 228-233 (2002)
8. Kolominsky-Rabas, P.L., Heuschmann, P.U., Marschall, D., Emmert, M., Baltzer, N., Neundorfer, B., Schoffski, O., Krobot, K.J.: Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen stroke project. Stroke 37(5), 1179-1183 (2006)
9. Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Thomas, B., Wardlaw, J.: A systematic review of the effectiveness, costeffectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol. Assess. 6(26), 1-112 (2002)
10. Chambers, M.G., Koch, P., Hutton, J.: Development of a decision- analytic model of stroke care in the United States and Europe. Value Health 5(2), 82-97 (2002)
11. Ehlers, L., Andersen, G., Clausen, L.B., Bech, M., Kjolby, M.: Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38(1), 85-89 (2007)
12. Ehlers, L., Muskens, W.M., Jensen, L.G., Kjolby, M., Andersen, G.: National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 22(1), 73-81 (2008)
13. Fagan, S.C., Morgenstern, L.B., Petitta, A., Ward, R.E., Tilley, B.C., Marler, J.R., Levine, S.R., Broderick, J.P., Kwiatkowski, T.G., Frankel, M., Brott, T.G., Walker, M.D.: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology 50(4), 883-890 (1998)
14. Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J. Intern. Med. 246(6), 549-559 (1999)
15. Launois, R., Giroud, M., Megnigbeto, A.C., Le Lay, K., Presente, G., Mahagne, M.H., Durand, I., Gaudin, A.F.: Estimating the cost-effectiveness of stroke units in France compared with conventional care. Stroke 35(3), 770-775 (2004)
16. Mar, J., Begiristain, J.M., Arrazola, A.: Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc. Dis. 20(3), 193-200 (2005)
17. Mihalopoulos, C., Cadilhac, D.A., Moodie, M.L., Dewey, H.M., Thrift, A.G., Donnan, G.A., Carter, R.C.: Development and application of model of resource utilization, costs, and outcomes for stroke (MORUCOS): an Australian economic model for stroke. Int. J. Technol. Assess. Health Care 21(4), 499-505 (2005)
18. Samsa, G.P., Reutter, R.A., Parmigiani, G., Ancukiewicz, M., Abrahamse, P., Lipscomb, J., Matchar, D.B.: Performing costeffectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol. 52(3), 259-271 (1999)
19. Samsa, G.P., Matchar, D.B., Williams, G.R., Levy, D.E.: Costeffectiveness of ancrod treatment of acute ischaemic stroke: results from the stroke treatment with ancrod trial (STAT). J. Eval. Clin. Pract. 8(1), 61-70 (2002)
20. Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Wardlaw, J.: Costeffectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35(6), 1490-1497 (2004)
21. Sinclair, S.E., Frighetto, L., Loewen, P.S., Sunderji, R., Teal, P., Fagan, S.C., Marra, C.A.: Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19(9), 927-936 (2001)
22. Wardlaw, J.M., Seymour, J., Cairns, J., Keir, S., Lewis, S., Sandercock, P.: Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 35(11), 2477-2483 (2004)
23. Bonita, R., Beaglehole, R.: Recovery of motor function after stroke. Stroke 19(12), 1497-1500 (1988)
24. Collin, C., Wade, D.T., Davies, S., Horne, V.: The Barthel ADL index: a reliability study. Int. Disabil. Stud. 10(2), 61-63 (1988)
25. Gresham, G.E., Phillips, T.F., Labi, M.L.: ADL status in stroke: relative merits of three standard indexes. Arch. Phys. Med. Rehabil. 61(8), 355-358 (1980)
26. Loewen, S.C., Anderson, B.A.: Predictors of stroke outcome using objective measurement scales. Stroke 21(1), 78-81 (1990)
27. Mahoney, F.I., Barthel, D.W.: Functional evaluation: the barthel index. Md. State Med. J. 14, 61-65 (1965)
28. Rankin, J.: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott. Med. J. 2(5), 200-215 (1957)
29. van Swieten, J.C., Koudstaal, P.J., Visser, M.C., Schouten, H.J., van Gijn, J.: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5), 604-607 (1988)
30. Briggs, A., Claxton, K., Sculpher, M.: Decision modelling for health economic evaluation (Handbooks in health economic evaluation). Oxford University Press, Oxford (2006)
31. Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
32. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581-1587 (1995)
33. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M.H., et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017-1025 (1995)
34. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P.: Randomised double- blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 352(9136), 1245-1251 (1998)
35. Gage, B.F., Cardinalli, A.B., Owens, D.K.: The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch. Intern. Med. 156(16), 1829-1836 (1996)
36. Solomon, N.A., Glick, H.A., Russo, C.J., Lee, J., Schulman, K.A.: Patient preferences for stroke outcomes. Stroke 25(9), 1721-1725 (1994)
37. Lee, A.J., Huber, J., Stason, W.B.: Post stroke rehabilitation in older Americans. The medicare experience. Med. Care 34(8), 811-825 (1996)
38. Weiner, J.M., Illston, L.H., Hanley, R.J.: Sharing the burden: strategies for public and private long-term care insurance. Brokings Institute, Washington, DC (1993)
39. Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J. Intern. Med. 246(3), 309-316 (1999)
40. Wardlaw J.M., Zoppo G., Yamaguchi T., Berge E.: Thrombolysis for acute ischaemic stroke. Cochrane database. Syst. Rev. 3, CD000213 (2003)
41. Kwiatkowski, T.G., Libman, R.B., Frankel, M., Tilley, B.C., Morgenstern, L.B., Lu, M., Broderick, J.P., Lewandowski, C.A., Marler, J.R., Levine, S.R., Brott, T.: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med. 340(23), 1781-1787 (1999)
42. Dewey, H.M., Thrift, A.G., Mihalopoulos, C., Carter, R., Macdonell, R.A., McNeil, J.J., Donnan, G.A.: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 32(10), 2409-2416 (2001)
43. Samsa, G.P., Matchar, D.B., Goldstein, L., Bonito, A., Duncan, P.W., Lipscomb, J., Enarson, C., Witter, D., Venus, P., Paul, J.E., Weinberger, M.: Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am. Heart J. 136(4 Pt 1), 703-713 (1998)
44. Sherman, D.G., Atkinson, R.P., Chippendale, T., Levin, K.A., Ng, K., Futrell, N., Hsu, C.Y., Levy, D.E.: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with ancrod trial. JAMA 283(18), 2395-2403 (2000)
45. Counsell, C., Dennis, M., McDowall, M., Warlow, C.: Predicting outcome after acute and subacute stroke: development and validation of new prognostic models. Stroke 33(4), 1041-1047 (2002)
46. Dorman, P., Dennis, M., Sandercock, P.: Are the modified "simple questions" a valid and reliable measure of health related quality of life after stroke? United Kingdom collaborators in the international stroke trial. J. Neurol. Neurosurg. Psychiatry 69(4), 487-493 (2000